

# Saraswanti Anugerah Makmur (SAMF)

## A preferable proxy to palm oil

- SAMF is one of the leading local NPK fertilizer manufacturers with the 3<sup>rd</sup> largest production capacity (excluding SOE) at 600k MT per year (behind who Wilmar & Agrifert) from its 3 factories located in Java, Sumatra, and Kalimantan. SAMF's R&D background and brand presence allows them to serve Indonesia's major palm oil players such as DSNG, TBLA, STAA, Hartono Plantation, etc.
- CPO upstream players have been through a roller coaster in 2022 but overall prices has went up significantly with YTD average at IDR12,750/kg (FY20: IDR8,640/kg; FY21:IDR11,719/kg) due to Russia's invasion to Ukraine. Aside from vegetable oil supply shock, fertilizer is also one of the important commodities affected by the invasion. This encourages CPO players to ensure fertilizer supply for the next half/year and keep up the fertilizer application to maintain ample production. SAMF benefited from this and managed to increase its ASP by 53% in 9M22 (from FY21) after a relatively stagnant 4 years.
- Major raw materials include Urea (N), Phosphate (P), and Potassium (K), which were affected by Russian's invasion to Ukraine back in early 2022. Nevertheless, SAMF already secured all of its raw materials from local producers (i.e. Pupuk Indonesia) and imports (Russia and Middle East) which will last them until end of FY23. Although not fully, SAMF is able to partially passed-on raw materials increase and maintain its GPM at 24.6% in 9M22 (27.9%/25.6% in FY20/FY21)
- The national NPK fertilizer industry still has major room for growth as
  the annual demand reached ~10mn tonnes while the estimated total capacity
  is only at ~4.4mn tonnes. To fill that gap, Indonesia imported ~60% NPK
  fertilizer from various countries. According to BPS, Belarus and Russia
  accounts for 23% of total fertilizer imports, which further caused imbalance on
  the supply and demand.
- Therefore, SAMF is focusing on capacity expansion with optimum utilization rate. Currently, the plant is operating at a ~70% rate, capable of producing ~420k MT per year. SAMF had allocated roughly IDR160bn this year (80% realized as of 9M22) for an additional line in Mojokerto plant, which is targeted to come online in late 1Q23, to bring its total capacity to 700,000 MT.
- Going forward, SAMF plans to expand its capacity to near 1mn MT with a similar low capex per tonne by assembling new production lines.
- SAMF expects to generate IDR2.9tn revenue in FY22, a 2x YoY growth
  (85% realized as of 9M22) driven by ASP growth. We think that this number
  is reasonable given the sustaining high price of NPK fertilizer at approximately
  IDR10,500/kg as of Dec2022 (+30% YTD). Entering 2023, we can expect
  revenue growth to be driven by volume instead, capitalizing on the
  national supply shortage of NPK fertilizer.
- SAMF's balance sheet is highly geared with ~90% DER considering its
  business nature with high cashflow from operations financed by short-term
  loans. However, its EBIT/int expense is quite stable and healthy around

# **Company**

## **Notes**

### **Basic materials**

**December 13, 2022** 

12M rating

N-R

12M TP Upside


#### Stock Data

JCI (December 12)	6,734
Stock price (December 12, IDR)	492
Market cap (IDR bn)	2,521.5
Shares outstanding (mn)	5,125
52-week high/low (IDR)	1,205 / 388
6M avg. daily turnover (IDR bn)	1.2
Free float (%)	15.1
Major shareholders (%)	
PT Saraswanti Utama	74.3
Agnes Martaulina Dwi Saraswanti Haloh	o 1.6
Noegroho Harihardono	4.9
Yahya Taufik	2.7
Andreas Adhi Harsanto	1.3

#### Performance

	1M	6M	12M
Absolute (%)	9.6	5.6	-54.8
Relative to JCI (%)	13.6	6.5	-54.3

#### SAMF price trend



Source: Bloomberg

## Nicholas Kevin Mulyono

nicholas.k@kisi.co.id

6x. SAMF also consistently distributes dividends with a payout ratio of  $\sim$ 60% since its listing on 1Q20.


- Given the expected top-line and margins, SAMF is set to earn FY22 net profit of IDR322bn, a 2.34x jump YoY. This implies a cheap 7.8x FY22 PE valuation (vs regional peers at ~11x) with huge ROE of 35.5% (vs regional peers at 27.9%).
- For FY23, we should see additional volume of approximately ~52,500 MT assuming 70% utilization rate after the new production line fully kicks in after 1Q23. Even if FY23 ASP falls by 13%, we can still expect SAMF to record a YoY revenue growth.

Table 1. SAMF financial summary

	2018A	2019A	2020A	2021A	9M22
Sales (IDR bn)	1,204	1,283	1,409	1,852	2,450
GP (IDR bn)	355	361	392	475	589
OP (IDR bn)	185	194	207	248	365
NP (IDR bn)	82	92	114	165	220
EBITDA (IDR bn)	185	211	224	271	383
Net debt (IDR bn)	569	444	262	380	896
GP margin (%)	29.5	28.1	27.9	25.6	24.0
ROE (%)	14.2	15.5	16.6	20.7	35.6
Dividend yield (%)	-	-	3%	6%	8%
EPS (IDR)	22.6	21.0	22.2	32.3	42.9
BPS (IDR)	165.0	145.1	152.9	168.3	195.7
DPS (IDR)	11.4	10.6	10.3	17.4	16.7
PE (x)	21.7	23.4	22.2	15.2	
PB (x)	3.0	3.4	3.2	2.9	
EV/EBITDA (x)	12.7	12.2	12.4	10.7	


Source: Bloomberg, KISI

Fig 1. SAMF corporate structure



Source: Company, KISI

Fig 2. SAMF's capacity expansion




Source: Company, KISI

Fig 3. Regional non-subsidized NPK capacity




Fig 4. SAMF's revenue & margin trend



Source: Company, KISI

Fig 5. SAMF's production vol. and utilization rate



Source: Company, KISI

Fig 6. SAMF's sales vol. & ASP

Source: Company, KISI



Source: Company, KISI

Fig 7. SAMF's debt level





Fig 8. SAMF's ROE and ROA



Source: Company, KISI

Source: Company, KISI

Note: 2022 earning is based on management guidance

Table 2. SAMF product portfolio





















Source: Company, KISI

Table 3. SAMF's factory location (yellow) and distribution line (green)



Source: Company, KISI



Table 4. SAMF's peers

Company	Bloomberg ticker	Mkt Cap (USD m n)	PETTM(x)	EV/EBITDA TTM (x)	ROE TTM(%)
Saraswanti Anugerah Makmur	SAMF IJ Equity	161	8.7	6.9	35.6
NFC PCL	NFC TB Equity	186	15.3	NA	36.3
Oat Agrio Co Ltd	4979 JP Equity	131	7.5	5.9	22.2
CH Biotech R&D Co Ltd	6534 TT Equity	209	11.3	7.8	32.8
All Cosmos Biotech Holding	4148 TT Equity	124	9.5	5.9	18.9
Mangalore Chemicals & Fertilizer	MCF IN Equity	120	11.3	16.0	14.2
Khaitan Chemical & Fertilizer	KCF IN Equity	88	9.0	8.6	38.3
peers weighted average		858	11.1	6.7	27.9

Fig 10.

(mn tonnes)

30,000

25,000

20,000

15,000


10,000

5,000

2016

Source: Bloomberg, KISI

Fig 9. Indonesia fertilizer import by country



Source: BPS, KISI Source: Company, KISI

■Subsidized fertilizer

**SAMF** production line Fig 11.



Source: Company, KISI

**SAMF** raw materials warehouse Fig 12.

2017

Indonesia fertilizer market



2018

■ Compound fertilizer

Source: Company, KISI

9,052

2021

9,230

2020

■ Single fertilizer

8,899

2019

#### Saraswanti Anugerah Makmur Company notes (Non-rated)



#### Disclaimer

This Research Report ("Report") is prepared by PT Korea Investment and Sekuritas Indonesia, or its subsidiaries or its affiliates ("KISI").

By receiving this Report, you confirm that: (a) you have previously requested KISI to deliver this Report to you and you are legally entitled to receive the Report in accordance with Indonesian prevailing laws and regulations, and (b) you have fully read, understood and agreed to be bound by and comply with the terms of this Report as set out below. Your failure to comply with the terms below may constitute a violation of law.

All the material presented in this Report is under copyright to KISI. This Report is strictly confidential and is for private circulation only to clients of KISI. This Report is being supplied to you strictly on the basis that it will remain confidential and that you will maintain its confidentiality at all times. None of the parts of this material, nor its contents, may be copied, photocopied, or duplicated in any form of by any means or altered in any way, or transmitted to, or distributed to any other party without prior written consent of KISI.

This Report is based on the information obtained by KISI from sources believed to be reliable, however KISI do not make representations as to their accuracy, completeness or correctness. This Report is prepared for general circulation and for information purposes only and under no circumstances should it be considered or intended as an offer to sell or a solicitation of an offer to buy the securities referred to herein. KISI accepts no liability for any direct, indirect and/or consequential loss (including any claims for loss of profit) arising from the use of the material presented in this Report and further communication given or relied in relation to this document.

This Report is intended for circulation among KISI' clients only and does not consider any specific investment objectives, financial situation and the particular needs of any specific person who may receive this Report. The entire content of this Report is not and cannot not be construed or considered as an offer, recommendation, invitation or solicitation to enter into any transaction (including trading and hedging) relating to the securities, other financial instruments, and other form of investments issued or offered by the company(ies) covered in this Report. It is your own responsibility to: (a) independently evaluate the content of this Report, (b) consider your own individual investment objectives, financial situation and particular needs, and (c) consult your own professional and financial advisers as to the legal, business, financial, tax and other aspects before participating in any transaction in respect of the securities of company(ies) covered in this Report.

This report is not to be relied upon in substitution for the exercise of independent judgement. Past performance and analysis should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied, is made regarding future performance. Information, valuations, opinions, forecasts, and estimates contained in this report reflects a judgment at its original date of publication by KISI and are subject to change without notice, its accuracy is not guaranteed or it may be incomplete.

The views expressed in this Report reflect the personal views of the individual analyst(s) at KISI about the securities or company(ies) mentioned in the Report and the compensation of the individual analyst(s), is, or will be directly or indirectly related to the performance of KISI' activities. KISI prohibits the individual analyst(s) who prepared this Report from receiving any compensation, incentive or bonus based on specific investment banking transactions or for providing a specific recommendation for, or view of, a particular company (including those covered in the Report). However, the individual analyst(s) may receive compensation based on the scope of his/their coverage of company(ies) in the performance of his/their duties or the performance of his/their recommendations.

In reviewing this Report, you should be aware that any or all of the above activities of KISI and its officers, directors and employees, among other things, may give rise to real or potential conflicts of interest. KISI and its officers, directors and employees, including persons involved in the preparation or issuance of this report, may, to the extent permitted by law, from time to time participate or invest in financing transactions with the issuer(s) of the securities mentioned in this report, perform services for or solicit business from such issuers, and/or have a position or holding, or other material interest, or effect transactions, in such securities or options thereon, or other investments related thereto. In addition, it may make SAMFets in the securities mentioned in the material presented in this report. KISI may, to the extent permitted by law, act upon or use the information presented herein, or the research or analysis on which they are based, before the material is published.

Please note that the securities of the company(ies) covered in this Report might not be eligible for sale in all jurisdictions or to all categories of investors. The availability of those securities and your eligibility to invest in those securities will be subject to, among others, the prevailing laws of the relevant jurisdiction covering those securities. Furthermore, the value and income of any of the securities covered in this Report can fall as well as rise and an investor (including you) may get back less than invested. Future returns are not guaranteed, and a loss of original capital may be incurred.

PT Korea Investment and Sekuritas Indonesia is Securities Company Member of the Indonesia Stock Exchange, licensed, registered and supervised by the Indonesia Financial Services Authority (Otoritas Jasa Keuangan).

©Copyright 2019, PT Korea Investment and Sekuritas Indonesia